EP1970057A1 — Process for the preparation of stable pharmaceutical compositions of 2-(R) - (1-(R)-(3, 5- bis (trifluoromethyl) phenyl) ethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-(5-oxo-1H, 4H-1, 2, 4-triazolo) methylmorpholine (aprepitant)
Assigned to Sandoz AG · Expires 2008-09-17 · 18y expired
What this patent protects
The present invention relates to a process for the preparation of a stable pharmaceutical composition of 2-(R) - (1-(R)-(3,5- bis (trifluoromcthyl)phcnyl) ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo) methylmorpholine (aprepitant), with a view to increase its s…
USPTO Abstract
The present invention relates to a process for the preparation of a stable pharmaceutical composition of 2-(R) - (1-(R)-(3,5- bis (trifluoromcthyl)phcnyl) ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo) methylmorpholine (aprepitant), with a view to increase its solubility and bioavailability.
Drugs covered by this patent
- Emend (APREPITANT) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.